Discovery of Highly Selective PARP7 Inhibitors with a Novel Scaffold for Cancer Immunotherapy
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.3c01764 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Hongfeng Gu und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: China Pharmaceutical University, Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.
Abstract (Originalsprache)
PARP7 plays a crucial role in cancer immunity. The inhibition of PARP7 has shown potential in boosting the immune response against cancer, making it an attractive target for cancer immunotherapy. Herein, we employed a rigid constraint strategy (reduction in molecular flexibility) to design and synthesize a series of novel indazole-7-carboxamide derivatives based on the structure of RBN-2397. Among these derivatives, (S)-XY-05 was identified as the most promising PARP7 inhibitor (IC50: 4.5 nM). Additionally, (S)-XY-05 showed enhanced selectivity toward PARP7 and improved pharmacokinetic properties (oral bioavailability: 94.60%) compared with RBN-2397 (oral bioavailability: 25.67%). In the CT26 syngeneic mouse model, monotherapy with (S)-XY-05 displayed a strong antitumor effect (TGI: 83%) by activating T-cell-mediated immunity within the tumor microenvironment. Collectively, we confirmed that (S)-XY-05 has profound effects on tumor immunity, which paves the way for future studies of PARP7 inhibitors that could be utilized in cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
- Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, China.
Förderung
- China Pharmaceutical University
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
Zitieren
APA
Gu, H., Yan, W., Yang, J., Liu, B., Zhao, X., Wang, H., Xu, W., Wang, C., Chen, Y., Dong, Q., Zhu, Q., Xu, Y., & Zou, Y. (2024). Discovery of Highly Selective PARP7 Inhibitors with a Novel Scaffold for Cancer Immunotherapy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01764
Vancouver
Gu H, Yan W, Yang J, Liu B, Zhao X, Wang H, et al. Discovery of Highly Selective PARP7 Inhibitors with a Novel Scaffold for Cancer Immunotherapy. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.3c01764
BibTeX
@article{Gu2024,
author = {Gu, Hongfeng and Yan, Wenxin and Yang, Jieping and Liu, Beibei and Zhao, Xiaolin and Wang, Hongxia and Xu, Wenbo and Wang, Chenghao and Chen, Yang and Dong, Qiuyi and Zhu, Qihua and Xu, Yungen and Zou, Yi},
title = {Discovery of Highly Selective PARP7 Inhibitors with a Novel Scaffold for Cancer Immunotherapy},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.3c01764}
}
EUVIMED